
Joint autumn report from the leading economic research institutes on the German economy
AI-generated summary
The joint autumn report from the leading economic research institutes regularly assesses the economic situation in Germany.
The leading economic research institutes are more confident about the German economy for the next two years, but are sobering about 2028. They increased their growth forecast for gross domestic product (GDP) this year to 1.3 percent and to 1.1 percent for 2027, as shown on Thursday in the institutes' joint autumn report.
The joint diagnosis is called “Upswing with structural problems - financial policy on the wrong track.” The institutes only expect significantly lower economic growth of 0.4 percent for 2028. This would be little more than the growth potential that has diminished in recent years.

Volkswagen is facing a gigantic recall of around four million vehicles worldwide due to a steering problem. In addition to VW and Audi, Skoda and Seat are also affected.

After chaotic conditions and overcrowded shuttles to the Grünheide gigafactory, Tesla deployed security personnel on buses. Plant management and the works council are demanding more discipline from the workforce when dealing with voluntary company services.

The federal government and the state of Hesse are withdrawing completely from the Condor airline. The British majority shareholder Attestor will take over the remaining 49 percent shares in August 2027 by exercising a purchase option.

Former Amazon executives have analyzed 20 management techniques of the US company in the book “The Secret Playbook”. The Handelsblatt exclusively highlights which methods can be successfully transferred to other companies and what the limits are.

The Düsseldorf-based insurance group Ergo is appointing the head of its US subsidiary Next Insurance, Guy Goldstein, to the board as Chief Artificial Intelligence Officer on October 1st. He replaces Mark Klein, who is leaving the company.

Novo Nordisk's capital market day in London disappoints investors despite plans for new blockbusters by 2030. The share continues to lose value, while US competitor Eli Lilly dominates with strong profit growth.